查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
炎症性肠综合症治疗市场 - 预测 2023-2028
市场调查报告书
商品编码
1279593

炎症性肠综合症治疗市场 - 预测 2023-2028

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

炎症性肠综合征 (IBS) 治疗市场预计 2021 年价值为 225.29 亿美元，在预测期内出现强劲增长。 炎症性肠综合征是一种慢性胃肠道疾病，会影响大肠（结肠）并引起腹痛、腹胀、腹泻和便秘等症状。 这是一种复杂的疾病，尚无确定的治疗方法，其确切原因尚不清楚。 因此，IBS 行业提供了多种旨在控製或减轻这种症状的药物和治疗方法。 这些治疗大致分为两种类型：药物治疗和非药物治疗。 泻药、止泻药、解痉药和抗抑郁药只是药理上用于治疗肠易激综合征的少数药物。 通过关注特定的肠易激综合症症状，例如肠收缩力下降、排便频率增加和情绪升高，这些药物可以减轻症状。

饮食改变（例如增加纤维摄入量和避免某些触发食物）和生活方式改变（例如压力管理和锻炼）是 IBS 非药物治疗的例子。 补充或替代治疗包括针灸和催眠疗法，一些患者可能会发现这些疗法有用。 新型创新疗法的开发、患病率的上升以及患者和医疗保健专业人员对 IBS 认识的提高预计将在未来几年推动 IBS 治疗市场的增长。 然而，市场也必鬚麵对一些问题，例如一些药品价格高，以及目前的治疗方法对一些患者无效等。

炎症性肠综合征药物市场是由 IBS 病例数量和认识以及诊断方法的引入和改进所驱动的。

  • 炎症性肠综合征患病率的上升是推动 IBS 治疗市场的主要因素之一，并受到饮食、生活方式和肠道微生物群变化等多种变量的推动。 也有人指出，肠道菌群的变化与IBS的发病以及这些生活习惯有关。 根据美国国家糖尿病、消化和肾臟疾病研究所 (NIDDK) 的数据，IBS 影响着 25 至 4500 万美国人。 提高患者和医疗保健专业人员对 IBS 的认识也是推动 IBS 药物市场的关键因素。 对这个问题的深入了解可以导致更早的诊断和治疗，从而改善患者的治疗结果。 诊断技术的改进也促进了 IBS 治疗市场的增长，从而提高了诊断 IBS 的准确性和效率。 近年来开发了几种诊断测试来帮助确诊肠易激综合症并排除可能出现类似症状的其他疾病。 例如，美国胃肠病学会建议使用某些诊断方法（例如结肠镜检查和粪便钙卫蛋白测定）来诊断 IBS。 此外，2020 年，美国食品和药物管理局 (FDA) 批准替那醇用于治疗成人便秘 IBS。

市场增长的主要挑战是治疗成本高昂以及治疗解决方案的知识和效率有限。

许多现有的 IBS 治疗方法仅部分有效，导致许多患者的症状缓解不充分。 例如，解痉药和抗抑郁药具有显着的副作用，在用于治疗肠易激综合症时可能会限制其耐受性。 此外，一些较新的 IBS 治疗方法（例如生物製剂）价格昂贵，并且对某些患者来说可能难以获得。 这些原因都极大地阻碍了IBS药物市场的发展。

亚太地区和北美在炎症性肠综合征药物市场中占据很大份额。

炎症性肠综合征治疗市场按地理位置划分为北美、南美、欧洲、中东和非洲以及亚太地区。 由于IBS发病率高且拥有许多大型製药公司，北美预计将在IBS全球市场中占据很大份额。 据加拿大肠病学会称，IBS 估计影响 5% 至 20% 的加拿大人。 此外，该地区拥有发达的医疗基础设施和高水平的肠易激综合症一般和专业知识。 因此，开发针对这种疾病的新颖且创造性的治疗方法已成为当务之急。

由于该地区人口庞大且不断增长，以及该疾病患病率不断上升，预计亚太地区 IBS 治疗市场将大幅增长。 此外，肠易激综合症在该地区变得越来越广为人知，增加了对诊断和治疗方案的需求。 此外，许多大型製药公司已向该地区扩张，加大研发投入。

内容

第 1 章简介

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第 2 章研究方法

  • 调查数据
  • 调查设计
  • 验证

第 3 章执行摘要

  • 调查要点

第 4 章市场动态

  • 市场促进因素
  • 市场抑制因素
  • 波特五力分析
  • 行业价值链分析

第 5 章炎症性肠综合症药物市场：按类型

  • 简介
  • 伴有腹泻的炎症性肠综合症 (IBS-D)
  • 伴有便秘的炎症性肠综合症 (IBS-C)
  • 感染后 IBS (IBS-PI)
  • 其他

第 6 章炎症性肠综合症药物市场：按治疗类型划分

  • 简介
  • 医学
  • 心理治疗
  • 膳食补充剂
  • 其他

第 7 章炎症性肠综合症药物市场：按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他
  • 中东和非洲
    • 沙特阿拉伯
    • 以色列
    • 阿拉伯联合酋长国
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 越南
    • 印度尼西亚
    • 其他

第 8 章竞争格局与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 合併、收购、协议与合作
  • 供应商竞争力矩阵

第 9 章公司简介

  • AbbVie Inc.
  • Ironwood Pharmaceuticals
  • Bayer AG
  • Probi AB
  • Salix Pharmaceuticals
  • Cosmo Pharmaceuticals
简介目录
Product Code: KSI061614661

The inflammatory bowel syndrome (IBS) treatment market was valued at US$22.529 billion in 2021 and will witness robust growth over the projected period. Inflammatory bowel syndrome is a chronic digestive disorder that affects the large intestine (colon) and causes symptoms such as abdominal pain, bloating, diarrhea, and constipation. It is a complicated illness with no known cure, and its precise cause is unclear. As a result, the IBS industry offers various medications and therapies designed to control and lessen the condition's symptoms. The two primary categories of these treatments are pharmacological and non-pharmacological. Laxatives, anti-diarrheal medicines, antispasmodics, and antidepressants are a few examples of the pharmaceuticals used pharmacologically to treat IBS. By focusing on particular IBS symptoms, such as decreased bowel contractions, increased frequency of stools, or mood enhancement, these drugs seek to alleviate the symptoms of the condition.

Dietary changes, such as increasing fiber intake or avoiding particular trigger foods, and lifestyle improvements, such as stress management and exercise, are examples of non-pharmacological therapy for IBS. Additional treatment options like supplementary and alternative therapies include acupuncture or hypnosis, which some patients may find helpful. The development of novel and innovative treatments, the rising prevalence of the illness, rising awareness of IBS among patients and healthcare professionals, and other factors are projected to fuel the growth of the IBS treatment market in the upcoming years. However, the market also has to contend with issues like the high cost of some pharmaceuticals and the ineffectiveness of some patients' present treatments.

The inflammatory bowel syndrome treatment market is driven by the rising cases and awareness of IBS and by the introduction and improvements in diagnostic procedures.

  • The rising prevalence of inflammatory bowel syndrome is one of the main factors driving the IBS treatment market, which is caused by various variables such as changes in food, lifestyle, and gut microbiota. Changes in gut flora have also been linked to the development of IBS and these lifestyle factors. IBS affects between 25 and 45 million Americans, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • Increasing awareness of IBS among patients and healthcare professionals is another important factor driving the IBS treatment market. Advanced knowledge of the issue may result in earlier diagnosis and treatment, improving patient outcomes.
  • Improvements in diagnostic technology are also fuelling the growth of the IBS treatment market, which increases the precision and efficiency of IBS diagnosis. Recent years have seen the development of several diagnostic tests that can help confirm an IBS diagnosis and rule out other illnesses that might present with comparable symptoms. For example, the American College of Gastroenterology suggests using certain diagnostic procedures to diagnose IBS, including colonoscopies and fecal calprotectin assays. The U.S. Food and Drug Administration (FDA) also approved tenapanor in 2020 for treating IBS with constipation in adults.

The key challenges to the market growth are high-cost treatments and limited knowledge and efficiency of treatment solutions.

Since many available IBS treatments are only partially effective, many patients only get insufficient symptom relief. Antispasmodics and antidepressants, for example, might have considerable adverse effects that restrict their acceptability when used as IBS therapy. In addition, some of the more recent IBS medications, such as biologics, can be pricey, which limits some patients' access to them. These reasons significantly hamper the development of the IBS treatment market.

Market Developments

  • In May 2022, the Indian Council of Medical Research (ICMR) released the IBD NutriCare App for patients suffering from inflammatory bowel disease (IBD). The ICMR, a group of gastroenterologists, dieticians, and app developers from AIIMS, collaborated to create the IBD NutriCare App targeted at the IBD population in India. It offers real-time data that informs the nutritionist or dietician about compliance problems, inaccurate entries, and inaccurate information, assisting in launching early and prompt nutritional interventions and creating individualized diet programs. It is mainly concentrated on the ease of large-scale data collecting and personalized tele-nutrition counseling that can improve the general clinical practice of dietary control and nutrition in IBD in a resource-constrained country like India.

Asia Pacific and North America accounted for a major share of the inflammatory bowel syndrome treatment market.

The inflammatory bowel syndrome treatment market is segmented geographically into North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is anticipated to control significant shares of the global IBS market due to the region's high incidence of the ailment and numerous big pharmaceutical companies. According to the Canadian Society of Intestinal Research, IBS is estimated to affect between 5% and 20% of Canadians. Additionally, the region has a strong healthcare infrastructure and high public and professional knowledge of IBS. As a result, developing novel and creative remedies for the illness has become a priority.

The Asia Pacific IBS treatment market is predicted to rise significantly due to the region's huge and expanding population and the ailment's rising prevalence. IBS is also becoming more widely known in the area, which has boosted the demand for diagnostic procedures and treatment alternatives. A number of significant pharmaceutical companies have also established operations in the area, which has increased investment in R&D.

Market Segmentation

By Type

  • Irritable Bowel Syndrome with Diarrhea (IBS-D)
  • Irritable Bowel Syndrome with Constipation (IBS-C)
  • Post-infectious IBS (IBS-PI)
  • Others

By Treatment Type

  • Medications
  • Psychological Therapy
  • Dietary Supplements
  • Others

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Vietnam
    • Indonesia
    • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Design
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Inflammatory Bowel Syndrome with Diarrhea (IBS-D)
  • 5.3. Inflammatory Bowel Syndrome with Constipation (IBS-C)
  • 5.4. Post-infectious IBS (IBS-PI)
  • 5.5. Others

6. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Medications
  • 6.3. Psychological Therapy
  • 6.4. Dietary Supplements
  • 6.5. Others

7. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East And Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. UAE
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Australia
    • 7.6.6. Vietnam
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. AbbVie Inc.
  • 9.2. Ironwood Pharmaceuticals
  • 9.3. Bayer AG
  • 9.4. Probi AB
  • 9.5. Salix Pharmaceuticals
  • 9.6. Cosmo Pharmaceuticals

Not an exhaustive list